+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Aclidinium"

From
Bronchitis - Pipeline Insight, 2024 - Product Thumbnail Image

Bronchitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
COPD in the United States: Understanding the COPD Patient Experience - Product Thumbnail Image

COPD in the United States: Understanding the COPD Patient Experience

  • Report
  • January 2024
  • 156 Pages
  • United States
  • 7 Results (Page 1 of 1)
Loading Indicator

Aclidinium is a long-acting muscarinic antagonist (LAMA) drug used to treat chronic obstructive pulmonary disease (COPD). It is administered via inhalation and works by relaxing the airways to improve breathing. Aclidinium is a relatively new drug, having been approved by the US Food and Drug Administration (FDA) in 2012. It is one of several respiratory drugs used to treat COPD, along with bronchodilators, corticosteroids, and combination therapies. Aclidinium is a popular choice for COPD treatment due to its long-acting effects and low risk of side effects. It is also used to prevent COPD exacerbations, which can be life-threatening. Aclidinium is available in both brand-name and generic forms. Some companies in the Aclidinium market include AstraZeneca, which manufactures the brand-name drug, and several generic drug manufacturers such as Mylan, Teva Pharmaceuticals, and Sandoz. Show Less Read more